Annovis Bio (ANVS) announced the publication of a new article in a peer-reviewed journal Biomolecules, which describes the pharmacokinetic, PK, profile of a new crystal form of buntanetap and compares it to the old form across several studies including mice, dogs, and humans. The new crystal buntanetap is currently being used in the pivotal Phase 3 clinical trial in patients with early AD, which is actively enrolling participants across the U.S. The study is designed to deliver two key readouts: symptomatic and disease-modifying. Moreover, this new form extends the intellectual property protection of the Company’s lead compound into the 2040s, covering its mechanism of action, therapeutic use, and combination with other drugs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Annovis Bio’s Promising Alzheimer’s Study: What Investors Need to Know
- Annovis Bio price target lowered to $10 from $12 at H.C. Wainwright
- Annovis Bio Reports Q2 2025 Progress and Financials
- Annovis Bio’s Promising Alzheimer’s Drug Trial: What Investors Need to Know
- Annovis Bio’s Strategic Advancements and Phase 3 Study Progress Support Buy Rating